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Prediction models often yield inaccurate predictions for new individuals. Large
data sets from pooled studies or electronic healthcare records may alleviate
this with an increased sample size and variability in sample characteristics.
However, existing strategies for prediction model development generally do not
account for heterogeneity in predictor-outcome associations between different
settings and populations. This limits the generalizability of developed models
(even from large, combined, clustered data sets) and necessitates local revisions.
We aim to develop methodology for producing prediction models that require
less tailoring to different settings and populations. We adopt internal-external
cross-validation to assess and reduce heterogeneity in models’ predictive perfor-
mance during the development. We propose a predictor selection algorithm that
optimizes the (weighted) average performance while minimizing its variability
across the hold-out clusters (or studies). Predictors are added iteratively until the
estimated generalizability is optimized. We illustrate this by developing a model
for predicting the risk of atrial fibrillation and updating an existing one for diag-
nosing deep vein thrombosis, using individual participant data from 20 cohorts
(N = 10 873) and 11 diagnostic studies (N = 10 014), respectively. Meta-analysis
of calibration and discrimination performance in each hold-out cluster shows
that trade-offs between average and heterogeneity of performance occurred. Our
methodology enables the assessment of heterogeneity of prediction model per-
formance during model development in multiple or clustered data sets, thereby
informing researchers on predictor selection to improve the generalizability to
different settings and populations, and reduce the need for model tailoring. Our
methodology has been implemented in the R package metamisc.
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1 BACKGROUND
Large combined clustered data sets are increasingly available, for example in so-called individual participant data
meta-analyses (IPD-MA) projects (where the data are clustered by study) and in studies using large scale electronic
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healthcare records (where the data are clustered by region, hospital, practice, etc).1 Such data sets are frequently used
to develop prediction models, to predict a current health status to aid in diagnosis or a future health outcome to pro-
vide a prognosis which may inform clinical decision making.2-4 Well-known examples are PHASES,5 INTERCHEST,6
S2TOP-BLEED,7 and EuroSCORE,8 all of which were developed using data from multiple centers or studies. Unfortu-
nately, prediction model studies that are based on IPD-MA or electronic healthcare records (EHR) rarely account for the
potential of between-cluster heterogeneity (eg, EuroSCORE8).9,10 Sometimes, parameters that capture the baseline risk
are stratified by cluster (eg, INTERCHEST6), but then usually no guidance is provided on how to use the prediction model
in new patients.
Although random effects models are generally recommended for dealing with the presence of clustering and hetero-
geneity of predictor effects, their implementation during prediction model development hampers the applicability of the
estimated regression coefficients. In particular, random effects modeling does not indicate which parameter values (for the
random intercept and predictor coefficients) should be used when the model is applied in new settings and populations.
Typically, a single value (eg, the mean) is used for these parameters when making predictions.
When new observations or whole new clusters become available, the common and random effects of the model may
be updated as new data become available, through the use of dynamic random effects methods.11 This can improve the
predictive performance of the prediction model in a validation setting. However, when the model is used to provide a
prediction for an individual that is not part of a known cluster, there is no information that can be used to update the
model, which eliminates the option of applying a dynamic method.
In general, a developed prediction model cannot generate accurate predictions in new patients when the true value
for its parameters (eg, the intercept term) varies across the targeted settings and populations, especially when the true
value of certain parameters is zero or has a reversed sign in some clusters. This heterogeneity may arise from differences
in observed and unobserved patient characteristics, differences in patients’ treatment and management strategies, differ-
ences in predictor and outcome definitions and differences in measurement methods across clusters. These differences
may be temporal, geographic, or domain in nature. A temporal validation, where the validation study is typically per-
formed with a similar study design and protocol by the same authors but in individuals selected from a later time period
as the development study, is considered to be the weakest form of external validation. Whereas small differences in the
study population or quality of care in a geographic validation may be present, in a domain validation the target popula-
tion or targeted outcome can be different. For instance, in a domain validation one may investigate whether a prediction
model developed in primary care is transportable to secondary or tertiary care.12
The impact of heterogeneity in predictive associations (ie, the effects of predictors in the included model) has been
well documented in the literature (Table 1).13,14 Many developed prediction models perform poorer than anticipated and
require local revisions prior to implementation.15 These revisions may involve a simple intercept update, a recalibration of
the linear predictor (ie, rescale all regression coefficients by a single value), the re-estimation of all the individual regres-
sion coefficients, or even the inclusion of new predictors.12,16-18 Unfortunately, revisions are rarely generalizable to other
settings and populations; several reviews have found that prediction model performance substantially varies across val-
idation studies.19,20 Therefore, such revisions, including recalibration and predictor selection, are preferably performed
during prediction model development. We consider situations where it is not possible (or very difficult) to define a priori
the potential source(s) of between-cluster heterogeneity, such as temporal calibration drift.21,22 We aimed to develop
methodology that is universally applicable, when causes of poor transportability cannot be directly addressed a priori.
The identification of between-cluster heterogeneity is not possible when data are available from only a single setting or
(sub)population. For this reason, the use of clustered data during prediction model development and its subsequent valida-
tion offers a critical opportunity to inspect whether this heterogeneity would actually be a concern when the model would
be implemented in clinical practice.9,10,13,14,23-28 However, actually resolving the presence of between-cluster heterogene-
ity (and thus ensuring model predictions are accurate for all clusters) remains a difficult challenge for which limited
guidance is available.29 For this reason, we here explore an alternative approach that aims to reduce this between-cluster
heterogeneity in prediction model performance and minimize the need for estimating setting-specific model parameters,
to thereby improve its generalizability.
Recently, internal-external cross-validation (IECV) has been introduced to assess the presence of heterogeneity of
a model’s performance during its development.10,23,25 IECV is a special case of cross-validation; available data are split
nonrandomly in a natural manner by iteratively taking each cluster (or study) as a hold-out sample. In each iteration, a
model is developed on the retained clusters, and then the model is tested in the hold-out cluster. A key advantage of this
is that it allows the transportability (ie, the generalizability to other populations and settings) of the model to be assessed
multiple times.
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T A B L E 1 Types of heterogeneity
• Within-cluster heterogeneity of (measured and unmeasured) covariate values. This heterogeneity is necessary to allow for
individual risk prediction
• Between-cluster heterogeneity in the distribution (eg, mean and SD) of predictor values. This heterogeneity may appear
when clusters represent different geographic regions, countries or studies, etc
• Between-cluster heterogeneity in baseline risk (eg, outcome incidence). This is often related to between-cluster
heterogeneity in eligibility criteria (eg, randomized trial versus observational study or between settings with differences in
patient management), or to between-cluster heterogeneity in unmeasured predictor values
• Between-cluster heterogeneity of predictor-outcome associations (and thus in the estimated model coefficients). These
differences may, for instance, appear when combining data from studies with differences in patient management, variable
and outcome definitions, etc
• Between-cluster heterogeneity of prediction model performance. The “true” performance of a prediction model may vary
between clusters due to differences in their underlying predictor-outcome associations, or due to differences in their
distribution of (measured or unmeasured) predictor values13,14,31
T A B L E 2 Highlights
• Many studies have shown that overfitting can lead to poor performance when predicting the outcome in new participants,
but also that this can be resolved by utilizing large data sets35-37
• Prediction models may still perform poorly even when overfitting is not an issue. This situation can occur when predictor
effects do not transport well across different settings.10,38,39 SIECV aims to address this issue, by incorporating this
transportability in the model building process
• SIECV is designed for situations where it is difficult to locally update model predictions. It aims to yield a global model
with stable performance across the relevant settings and (sub)populations, and may therefore have suboptimal
performance within (some of the) individual clusters, particularly when they differ much from one another
• SIECV can help to find an appropriate balance between a model’s internal and external validity, and to limit the need for
local revisions (by avoiding heterogeneity in predictor-outcome associations)
• SIECV does not address miscalibration-in-the-large. This can be resolved using a relatively simple update of the model’s
intercept term, and will often remain necessary.18,40 Finally, access to clustered data allows one to estimate multiple
intercept terms, and thus to ascertain under which conditions an intercept update may be necessary9,13
In this article, we will first revisit the IECV framework for assessment of model performance in large clustered data
sets (Section 2). For the highlights of this article, see Table 2. We then extend the IECV framework to inform predictor
selection during prediction model development in Section 3, in order to identify and reduce their impact on the model’s
performance within and across clusters in the large combined data set. We then apply the methods in our motivating
examples in Sections 4 and 5. Finally, we provide a discussion in Section 6. Our methodology can be applied using the
metapred function in the R package metamisc.30
2 INTERNAL-EXTERNAL CROSS-VALIDATION FOR MODEL VALIDATION
Resampling procedures allow the optimal use of the available data, as all data can be used for model development and
subsequent evaluation. Traditionally in cross-validation procedures, the data are iteratively split into a development and
validation set by randomly sampling without replacement. In each iteration, a model is estimated on the development
sample and predictions are made for the random validation sample. The performance of these predictions in the validation
samples is then averaged across iterations, thereby giving an estimate of the reproducibility of model performance.
When data are clustered across different studies or settings, traditional resampling procedures that do not account for
clustering cannot directly be applied.32 For this reason several extensions have been proposed that preserve the clustering
within and the heterogeneity across the generated samples. In the so-called internal-external cross-validation approach,
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the data are split by cluster, which may represent the studies from an IPD-MA or the centers in data from EHR.23,25,26 A
model is then iteratively fit in K-1 clusters (Section 2.1) and its corresponding performance model performance is calcu-
lated in the remaining cluster (Section 2.2). This is repeated K times, so that, provided that sufficient data are available
in the development and validation clusters, a performance estimate and its SE is available for each of the clusters. Thus,
IECV is cross-validation where the hold-out samples are nonrandom, in the presence of between-cluster heterogeneity.
IECV therefore allows the study of a developed model’s potential transportability multiple times. Note that if all patients
are exchangeable across clusters, IECV corresponds to the traditional cross-validation and assesses model reproducibility
(rather than transportability).10
In contrast to traditional cross-validation, estimates of the performance in the hold-out samples cannot sim-
ply be averaged, as the variation within and across clusters needs to be taken into account. This can be achieved
by adopting a (fixed effect or random effects) meta-analysis of the performance estimates (Section 2.2),33 or by
weighting the performance estimates by the number of events in each cluster.34 As the data are split nonran-
domly, this allows the transportability (ie, the generalizability to other populations and settings) of the model to be
assessed.
2.1 Model fitting
The development phase of IECV may involve a one-stage or a two-stage IPD-MA approach. In the two-stage approach,
the prediction model is fitted separately in each cluster. The model coefficients estimated in each of the development
K-1 clusters are then combined using standard meta-analysis techniques. In the one-stage approach, a generalized linear
model (GLM) is estimated in each of the K development samples consisting of K − 1 clusters. This model may account
for clustering by including random intercepts and/or slopes for within-cluster covariates.13,14,29,34 A disadvantage of the
one-stage approach in IECV is that the data from each cluster needs to be used K-1 times to fit a model in the one-stage
approach. On the other hand, in the two-stage IECV approach the data from each cluster only needs to be used for model
fitting once, as the second stage comprises meta-analysis of different combinations of coefficients and their SEs. The
two-stage approach may therefore substantially reduce the necessary computational performance time. However, the
two-stage approach may not be feasible when clusters are relatively small, as parameters then become difficult to estimate.
For this reason, the two-stage approach appears beneficial when most clusters (studies) in the meta-analysis are not small,
and we adopt this approach in our article.
Let xp, k, j be the value of a prespecified predictor p, p = 1,… ,P (or function thereof) measured in individual patients
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p,(h)), where tQ−1,1−𝛼∕2 is the upper 𝛼∕2 quantile of a t-distribution with Q− 1 degrees of free-
dom, varHK(𝛽
MA
p,(h)) is a modified variance estimate and Q=K − 1 as one cluster is held out for validation.41-45 The
extent of heterogeneity of a predictor effect can be explored by quantifying a prediction interval (PI), which esti-







p,(h)).46,47 A wide prediction interval for the predictor effect indicates that the predic-
tor effect may be very different in a new cluster, which makes it unlikely that the predictor will improve the model’s
predictions for individuals in a new cluster.
The random effects meta-analysis model is preferably estimated with REML or the Paule-Mandel method.48-51 When
fewer than 10 clusters are included in the meta-analysis, or when some clusters are small or the outcome is rare, the
between-cluster heterogeneity cannot be reliably estimated by any currently available method.51 The estimated coeffi-
cients could also be summarized using multivariate meta-analysis methods,33,52 which may be helpful in the presence of
collinearity and missing parameter estimates. The necessary within-cluster covariances can then directly be estimated
from the IPD set at hand. However, usually univariate and multivariate meta-analysis methods give very similar results
when all of the parameter estimates of interest are available for all clusters, even when correlations are large.53 In IECV,
all parameters can be estimated from the data hand, meaning that univariate meta-analysis will usually suffice.
2.2 Assessing external model validity
In each iteration of the IECV, the developed model is validated in individuals from the hold-out cluster by applying the
model (as developed in the other clusters) using the observed predictor values of individuals. If the developed model
contains random (or stratified) intercept terms or predictor effects, this also requires choices about which parameter
values are to be used when applying the developed model.
It may be fruitful to select an intercept or predictor effect that best fits the validation cluster,13 provided that sufficient
data are available for the validation cluster. Alternatively, given that the prediction model is mean centered and the overall
frequency of the outcome is known for the population or cluster that the model is applied to, the appropriate intercept
can be restored.13 When no such options are available, one may choose to apply the mean of the random intercept or
predictor effects. Recent work shows that in terms of calibration the latter outperforms marginal models and models that
ignore clustering during model development.54
When comparing the risk predictions for the hold-out cluster with the observed outcomes, several performance mea-
sures such as the c-statistic, calibration slope, calibration-in-the-large and/or mean square error can be calculated.10,27,55
This process is repeated until each cluster has been used as a hold-out cluster once, yielding a set of performance statis-
tics for each IECV iteration. The corresponding estimates can then be pooled across the hold-out clusters using random
effects meta-analysis methods, though some statistics and their SEs may require transformation first.29,33,56 Similar to the
predictor effects, a prediction interval can then be constructed for the performance estimates, which provides an interval
of likely values that the performance statistic will have in a new cluster.
Besides allowing one to obtain an average estimate of performance, meta-analysis is particularly helpful for investi-
gating the presence of heterogeneity of prediction model performance and any possible causes thereof.10,31,33 Prediction
model performance may vary across clusters due to imprecision or bias of the regression coefficients or performance esti-
mates, or due to the variation in population characteristics. Disentangling these various sources of variation is necessary
when inferring on the model’s potential generalizability to different settings and populations.
Finally, if the average performance and heterogeneity of the performance of the prediction model are deemed ade-
quate, that is it is considered likely that performance will be adequate in a new cluster, a so called global model may be
developed by estimating the coefficients for the predictors on the data of all available clusters. In this final step no clusters
are left out, in order to minimize the variability of the estimates of the coefficients.25
2.3 Motivating example: Diagnosis of deep vein thrombosis
Patients with a deep vein thrombosis (DVT) have an increased risk of post-thrombotic syndrome and pulmonary
embolism, which can be fatal.57 In the majority of patients in whom DVT is suspected, no DVT is present on advanced
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(reference) testing.58 For illustrative purposes, we here consider the diagnosis of DVT in patients that are suspected of
having DVT and use the IPD of 10 014 patients from 11 studies,59 where each study is considered one cluster (Tables 3
and 4). In each cluster separately, we estimated a binary logistic regression model with three prespecified predictors: his-
tory of malignancy (yes/no), calf difference (difference in circumference of the calves ≥ 3 cm), recent surgery (yes/no).
Preferably, a continuous predictor such as calf difference should not be dichotomized, as this leads to a loss of informa-
tion. However, the continuous predictor was not available in the data at hand. As some clusters were small, we applied
Firth’s correction,60 which yields unbiased Maximum Likelihood estimates for the coefficients and SEs in small samples61
and adjusted the intercept post hoc by re-estimating it with an unpenalized GLM.62 We then applied IECV and adopted a
two-stage approach for prediction model development. The pooled regression coefficients (including the intercept term)
from the development clusters were used for generating predictions in the hold-out cluster. Although Firth’s correction
still yielded estimates with high variance for the predictor coefficients in some clusters, this was mitigated by performing
a meta-analysis of the regression coefficients.
Results in Table 4 reveal that estimates for the predictor effects were very heterogeneous across the included clusters.
For example, the coefficient for malignancy was 0.90 (SE: 0.33) in cluster 1 and 1.69 (SE: 0.22) in cluster 7. Similarly, the
coefficient for calf difference was 0.98 (SE: 0.15) in cluster 2 and 1.68 (SE: 0.13) in cluster 4. As indicated in Table 5 this
also resulted in heterogeneous model performance estimates across hold-out clusters. Although calibration was good on
average, it was highly variable in individual clusters. For instance, whereas the summary calibration-in-the-large equaled
0.03 (95% CI: −0.33 to 0.39), meaning that calibration-in-the-large was very good on average, the calibration-in-the-large’s
approximate 95% prediction interval (PI) ranged from −1.22 to 1.27, thereby indicating the presence of heterogeneity
of the prediction model’s calibration. Similarly, the calibration of the linear predictors was very good on average, as the
calibration slope (also estimated with Firth’s correction) equaled 1.00 (95% CI: 0.83 to 1.16), whereas the approximate
95% PI for the calibration slope ranged from 0.53 to 1.46. Further, the c-statistic equaled 0.68 (95% CI: 0.65 to 0.71) and
was also substantially heterogeneous across clusters (approximate 95% PI: 0.60 to 0.75).
On overall, the IECV showed that the modeling strategy was unlikely to yield a prediction model with good gen-
eralizability. Substantial revision would be necessary to improve the model’s average discrimination performance and
to reduce the heterogeneity of its calibration and discrimination performance. A possible approach would be to refine
the original modeling strategy by altering the set of included predictors and by considering interaction effects and/or
Outcome: DVT No Yes Total
Sex Female 5174 (83.8) 1001 (16.2) 6175
Male 2943 (76.7) 896 (23.3) 3839
Malignancy No 7600 (82.8) 1581 (17.2) 9181
Yes 517 (62.1) 316 (37.9) 833
Recent surgery No 7333 (82.4) 1569 (17.6) 8902
Yes 784 (70.5) 328 (29.5) 1112
Leg trauma No 5210 (77.1) 1544 (22.9) 6754
Yes 2907 (89.2) 353 (10.8) 3260
Vein distension No 7257 (82.5) 1538 (17.5) 8795
Yes 860 (70.5) 359 (29.5) 1219
Calf difference >3 cm No 6160 (88.0) 843 (12.0) 7003
Yes 1957 (65.0) 1054 (35.0) 3011
D-dimer abnormal No 4392 (97.0) 137 (3.0) 4529
Yes 3725 (67.9) 1760 (32.1) 5485
Age Mean (SD) 58.8 (17.4) 61.1 (17.1) 10 014
Duration of symptoms Mean (SD) 22.8 (45.5) 27.0 (60.5) 10 014
Abbreviation: DVT, deep vein thrombosis.
T A B L E 3 Clinical characteristics of
DVT data
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T A B L E 4 Estimated regression coefficients (and SEs) for predicting DVT in each of 11 clusters
Cluster Intercept Malignancy Calf difference Surgery
1 −2.46 (0.14) 0.90 (0.33) 1.17 (0.19) 0.04 (0.35)
2 −0.95 (0.11) 0.31 (0.24) 0.98 (0.15) 0.17 (0.25)
3 −2.92 (0.44) 1.57 (0.87) 1.59 (0.50) 1.73 (0.54)
4 −1.92 (0.09) 0.63 (0.16) 1.68 (0.13) 0.83 (0.17)
5 −2.27 (0.16) 0.24 (0.42) 1.03 (0.20) 0.52 (0.26)
6 −2.25 (0.12) 1.23 (0.30) 1.40 (0.17) 0.51 (0.21)
7 −3.18 (0.13) 1.69 (0.22) 1.41 (0.19) 0.26 (0.31)
8 −1.72 (0.18) 1.02 (0.58) 1.24 (0.27) 0.78 (0.51)
9 −2.01 (0.11) 0.80 (0.25) 1.25 (0.14) 0.37 (0.19)
10 −2.16 (0.18) 1.04 (0.46) 0.65 (0.34) 0.79 (0.35)
11 −2.30 (0.19) 1.65 (0.26) 1.32 (0.23) 0.82 (0.27)
Summary estimate −2.17 (0.18) 0.98 (0.17) 1.27 (0.08) 0.55 (0.09)
Approximate 95% prediction interval −3.33:−1.01 0.08:1.88 0.86:1.67 0.20:0.90
Note: Malignancy: history of malignancy; Calf difference: difference in circumference of calves ≥ 3 cm; Surgery: recent surgery. Summary
estimates and prediction intervals for global model.
Abbreviation: DVT, deep vein thrombosis.
T A B L E 5 Internal-external
cross-validation performance
estimates and SEs for the
predefined model for predicting
DVT
Hold-out cluster for validation Slope (SE) CIL (SE) c-Statistic (SE)
1 0.86 (0.15) −0.44 (0.10) 0.65 (0.02)
2 0.63 (0.11) 1.06 (0.08) 0.63 (0.02)
3 1.49 (0.35) −0.24 (0.22) 0.78 (0.05)
4 1.18 (0.10) 0.43 (0.06) 0.72 (0.01)
5 0.73 (0.15) −0.33 (0.10) 0.65 (0.02)
6 1.12 (0.14) −0.00 (0.08) 0.70 (0.02)
7 1.24 (0.14) −0.93 (0.09) 0.71 (0.02)
8 1.02 (0.24) 0.51 (0.13) 0.67 (0.03)
9 0.92 (0.11) 0.12 (0.07) 0.68 (0.02)
10 0.71 (0.27) −0.09 (0.14) 0.62 (0.04)
11 1.27 (0.17) 0.15 (0.11) 0.74 (0.03)
Summary estimates 1.00 (0.08) 0.03 (0.16) 0.68 (0.06)
Approximate 95% prediction interval 0.53:1.46 −1.22:1.27 0.60:0.75
Note: Slope: calibration slope.
Abbreviations: CIL, calibration-in-the-large; DVT, deep vein thrombosis.
nonlinear terms. It is generally recommended to define a set of predictors and functions and interactions thereof on
beforehand. Recommendations for this are given elsewhere.2,63-65
Subsequently, the revised model should be validated again, after which other revisions may be decided and so forth. It
may be clear that this strategy is very time consuming and may lead to arbitrary choices in predictor selection. For these
reasons we propose a formal framework for predictor selection in the context of heterogeneity of performance across
clusters in the next section. We address methods that aim to reduce heterogeneity of performance, improve the average
performance and a combination thereof. The code used to apply our methodology as presented in this article is available
on Github (https://github.com/VMTdeJong/SIECV-DVT).
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3 STEPWISE INTERNAL-EXTERNAL CROSS-VALIDATION FOR MODEL
DEVELOPMENT
In the previous section, we described the purpose of IECV to assess the generalizability of a prediction model that is
generated by a predefined modeling strategy. Here, we propose to extend IECV to optimize model generalizability during
its development. We here describe the algorithm for the situation that IECV will be used to expand an empty (intercept
only) model by iteratively adding predictors, functions of predictors and interaction effects.
We assume that these candidate predictors (and functions thereof) have already been selected through clinical reason-
ing and evidence from previous studies, such as reviews of prediction models and prognostic factor studies. The proposed
methodology is not intended for dimensionality reduction (eg, variable selection in settings with large P, small N), but is
used to assess the heterogeneity of the predictive performance resulting from including these in the prediction model.
The approach readily generalizes to the expansion or reduction of a given model. In this stepwise IECV (SIECV) for
prediction model development models are estimated, validated in external data sets, and updated in an iterative process,
as follows.
Denote the data from the kth cluster by Sk, and the data from a set of clusters excluding cluster h by S(h). Let
p, p= 0, 1, … , P be indicators to denote the candidate predictors (or functions thereof), where p= 0 indicates none. The
algorithm consists of up to I model adaptation cycles, where I generally equals P, the number of predictors available for
inclusion in the model. Then, let Pr(i) denote the set of candidate predictors for inclusion, where Pr(1)= {1, 2, … , P} and
Pr(0)= {0}.
Further, let Mi, p denote the models in cycle i with added predictor p in the stepwise process. Let Mi, p, (h) denote a
model estimated on data from all clusters excluding Sh. Let Ẑi,p,h be an estimate of performance (ie, a loss function) of
model Mi, p, (h) in cluster h, such as the mean squared error. Let Âi,p be the estimate of a loss function (ie, an aggregated loss
function or an estimate of heterogeneity, further described in Section 3.2) in cycle i for a model extended with predictor
p, and let c indicate a predictor p that has minimal Âi,p, such that Mi, c is the model with best generalizability in cycle i.
Then, the algorithm is defined as follows and starts at cycle i= 0:
1. For all p in Pr(i):
(a) Extend model Mi− 1, c with predictor p to generate new model Mi, p.
(b) For h, h= 1, … , K:
(i) Estimate the model Mi, p, (h) on S(h), preferably while taking clustering within clusters into account.
(ii) Predict ŷi,p,h,j for individual participants in hold-out sample Sk.
(iii) Estimate performance measure Ẑi,p,h and its SE ŜE(Ẑi,p,h) for predictions ŷi,p,h,j in Sh.
(c) Estimate aggregated loss function Âi,p on Ẑi,p,1, … , Ẑi,p,K and ŜE(Ẑi,p,1), … , ŜE(Ẑi,p,K).
2. Find the minimal Âi,p in this cycle. Denote this by Âi,c and its corresponding model by Mi, c.
3. The first condition that is satisfied:
(a) If i= 0, continue to step 1.
(b) Else, if Âi,c ≥ Âi−1,c, the algorithm stops and Mi− 1, c is returned as the final model.
(c) Else, if i= I, the algorithm stops and Mi, c is returned as the final model.
(d) Else, remove predictor c from the candidate predictor set Pr(i), increment i by 1 and continue to step 1.
Finally, if the performance of model Mi, c is deemed satisfactory, a so called global model is generated by estimating
the coefficients for the predictors in Mi, c on all available data. No clusters are left out in this final cycle, to reduce the
variance of the estimates of the coefficients.25
This global model however, is at risk of overfitting as a result of small sample bias, unless the sample is sufficiently
large and the event rate sufficiently high, even if no selection of predictors were applied.35,37,66 To account for this,
the prediction model could be fitted with penalized regression, such as Firth’s regression. To reduce the variance of
the estimated regression coefficients, the ridge penalty could be applied instead, or one could opt for a fully Bayesian
approach.
By considering the candidate predictors for inclusion, however, the prediction model is at further risk of overfitting.2,64
A straightforward adjustment for overfitting could be achieved with the calibration slope and calibration-in-the-large.67
In step 1 (b) iii of the final cycle these could be estimated and then summary meta-analyses estimates could be com-
puted. The final model coefficients (excluding the intercept) would then be multiplied by the summary calibration slope,
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whereas the summary calibration-in-the-large would subsequently be estimated and added to the global model’s inter-
cept, thereby yielding a final model. Ideally, however, the entire model selection procedure is to be performed within an
additional bootstrap or cross-validation procedure,68 as this would account for any overfitting introduced by the SIECV
itself. Alternatively, heuristic shrinkage, that shrinks the coefficients by a function of the number of predictors considered,
may be applied.2,64,69
3.1 Extensions
Throughout this article, we work from the perspective that an entirely new prediction model is to be developed. However,
our proposed framework readily encompasses model redevelopment including the adding and removal of predictor terms.
Predictors that are known from previous research to have a strong predictive effect can then be forced in the model
instead of applying a selection strategy to these predictors, as is generally recommended.65 Selection of predictor effects
may then also be performed with a backward procedure starting with all candidate predictors and their transformations
or interactions, rather than forward. Though, this may yield issues in the estimation when many predictor effects are
considered, especially when random effects are applied. In a simulation study (described in online supporting information
A, code on Github [https://github.com/VMTdeJong/SIECV-sim-DVT]), the forward and backward SIECV methods had
similar out-of-sample performance, both in terms of average performance and generalizability thereof.
Further, similar to IECV for model validation we may adopt a one- or two-stage approach (Section 2.1) for model
estimation. To enhance the interpretability of a prediction model, it is generally recommended to include main effects for
variables that are included as interaction effects. Hence, the algorithm may be adjusted so that this is always the case by
forcing the main effect to remain in the model whenever an interaction with another variable is included.
3.2 Quantifying model generalizability
The SIECV algorithm requires specification of an aggregated loss function (Ai, p) that is to be minimized, in order to
optimize generalizability of performance across clusters. Here, we consider parametric and nonparametric aggregated
loss functions, that vary with respect to the importance they place on the average and heterogeneity of performance.
3.2.1 Ignoring heterogeneity
As a first step, we consider a naive estimator of predictive performance across hold-out data sets from different clusters,
that ignores variation within and across clusters. This approach may be reasonable when the clusters are very large and
of similar size, and when the effect of clustering is negligible (that is when the intraclass correlation coefficient is near
zero). The overall performance is then given by the mean performance across clusters. For instance, when optimizing the








To incorporate the uncertainty of the predictive performance estimates into an aggregated loss function, it may be more
appropriate to adopt a weighting procedure. The meta-analysis framework (see Section 2.1) therefore appears an appeal-
ing choice. A straightforward extension to Equation (4) would be to apply the weighting procedure in described in
Equations (2) and (3). This allows to minimize the prediction error in an “average” cluster, but still does not attempt
to optimize their stability across clusters. As a result, it is possible that developed models perform well on average, but
require substantial local revisions before implementation. To reduce the need for local revisions, the aggregated loss func-
tion should account not only for the average performance, but also for its variation across clusters. For this reason, we
propose an extension that combines both sources of error:
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̂ARE𝜆i,p = 𝜆Ẑ
RE
i,p + (1 − 𝜆)𝜏 i,p, (5)
where 𝜆 is a hyperparameter that defines the impact of random effects meta-analysis summary estimate of perfor-
mance ẐREi,p and heterogeneity estimate 𝜏 i,p on aggregated loss function
̂ARE𝜆i,p . This is a parameter that is to be chosen
on beforehand, where its value should depend on the relative importance of average and heterogeneity of performance.
In the simplest case we let 𝜆 = 1, such that the estimate for generalizability is given by the mean of the distribution of
performance, ̂ARE1i,p = Ẑ
RE
i,p . Alternatively, if desired, we can set 𝜆 to 0, such that we can inform the selection of predic-
tors solely based on the reduction in heterogeneity of performance, yielding ̂ARE0i,p = 𝜏 i,p. Finally, we consider the case






ẐREi,p + 12𝜏 i,p.
This equation can be seen as an extension of the bias-variance decomposition of the MSE where we now
have a summation of squared bias, within-cluster variance and between-cluster variance. If p are considered esti-
mators for y, then the MSE for p can be shown to be: MSE(p) = var(p) + Bias(p, y)2. As 𝜏2 is the estimate of
the between cluster variance of MSE(p), that is, varbs, the estimator














var(p) + Bias(p, y)2
))
. (6)
Similar to the meta-analysis of prediction model coefficients discussed in Section 2.1 it is important to consider
the estimation of between-cluster heterogeneity in prediction model performance. For this reason, we recommend a
random effects meta-analysis to summarize estimates of prediction model performance. As discussed in Section 2.1,
the random effects meta-analysis model is preferably estimated with REML or the Paule-Mandel method. Estimates of
between-cluster heterogeneity can then be used to derive an approximate prediction interval that provides information
on the likely values that model performance may take in a new cluster. A sufficient number of clusters each with suffi-
cient observations as well as an adequate estimation method are necessary to make this approximate prediction interval
informative
3.2.3 Variability of performance across data sets
In the meta-analysis approach, the evidence from small clusters is downweighted to attain an estimate of the mean of
the distribution of performance. Yet this distribution might not be of central importance. Instead, all clusters might be
considered of equal importance. Then we may instead apply a measure of variability directly to the performance estimates,
for instance the SD ÂSDi,p = SD(Ẑi,p,1, … , Ẑi,p,K).
Alternatively, if no assumptions can be made on the distribution of the predictive performance statistics, we may apply






|Ẑi,p,v − Ẑi,p,h|. (7)
4 MOTIVATING EXAMPLE 2: UPDATING A MODEL FOR DIAGNOSING
DVT
The prediction model developed in Section 2.3 had a rather heterogeneous performance across validation clusters and was
lacking in average discrimination performance. This heterogeneity of performance implies that although the outcome
may be predicted well in individuals in some clusters, which may be helpful in diagnosis, it may be unsatisfactory for
individuals in other clusters. The prediction model performance heterogeneity across the 11 clusters may be explained by
differences in (measured and unmeasured) predictor distributions and true predictor effects. Therefore we here consider
whether additional predictors and interaction effects might explain such differences. Whereas individual clusters may
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lack the sample size to detect nonlinear effects or may lead to highly variable predictor effects, this is more feasible in
pooled studies such as for an IPD-MA and in large healthcare data bases.
Briefly, we considered the following ten additional candidate predictors to extend the model from Section 2.3: sex,
absence of leg trauma, absence of leg trauma × recent surgery (ie, an interaction effect), vein distension, log of duration of
symptoms, age/25 (ie, divided by 25, to increase the absolute value of its coefficient), age/25 squared, age/25×malignancy,
abnormal d-dimer value and abnormal d-dimer × sex. As we developed this model for illustrative purposes only,
we applied multiple imputation for missing data using a joint model with random effects, but have used only one
imputed data set for analyses.30,72 An overview of the missing data per variable per cluster is given in online supporting
information B.
We recommend that the inclusion of each candidate predictor (or transformation thereof) be carefully considered
with respect to the improvements in generalizability of the model performance on the one hand, and the cost and harms
relating to the measurement of the predictor on the other. Further, it is generally recommended that predictors that are
known from previous research to have a strong predictive effect should be forced in the model instead of applying a
selection strategy to these predictors.65 Accordingly, we force malignancy, calf difference and surgery as predictors into
the model in this example. We apply our methodology to illustrate how each of the strategies regarding heterogeneity of
performance leads to different model specifications, and thereby to differing average and heterogeneity of performance. To
assess the generalizability of prediction models that use these predictor functions, we follow the SIECV strategy for model
development that we developed in Section 3, apply the MSE (ie, Brier score) to the predicted probabilities in the hold-out
clusters and apply the aggregated loss functions (measures of heterogeneity of performance) on the MSE estimates and
SEs thereof, to select predictors as outlined in Section 3.2.
The six applied aggregated loss functions lead to models with four different predictor function specifications (Table 6),
as the strategy that ignored clustering (AM) when estimating generalizability of performance lead to the same model
specification as the strategy that optimized the meta-analytic mean of performance (ARE1 ), and the meta-analysis strat-
egy that placed equal importance on heterogeneity of performance and average performance (ARE1∕2 ) lead to the same
T A B L E 6 Estimated regression coefficients of seven models for predicting DVT estimated with (S)IECV
Predictor None AM ARE1 ARE1∕2 ARE0 ASD AGini
Intercept −2.17 −3.54 −3.54 −5.13 −5.00 −5.13 −3.99
Malignancy 0.98 0.76 0.76 1.64 1.68 1.64 2.05
Calf difference 1.26 1.13 1.13 1.38 1.34 1.38 1.07
Surgery 0.55 −0.04 −0.04 0.25 0.25 0.25 0.34
D-dimer positive 2.76 2.76 2.99 2.94 2.99 2.81
Age/25 −0.22 −0.22
Vein distension 0.46 0.46
Surgery × no leg trauma 0.68 0.68
No leg trauma 0.95 0.96 0.95
(Age/25)2 −0.02 −0.02
Male 0.32 0.36 0.32 0.52
D-dimer positive × male −0.20 −0.24 −0.2 −0.28
Malignancy × age/25 −0.32 −0.35 −0.32 −0.50
Note: Malignancy: history of malignancy; Calf difference: difference in circumference of calves ≥ 3 cm; Surgery: recent surgery;
Age/25: age divided by 25; Duration: duration of symptoms; None: model with no predictor selection. Empty cells indicate the
predictor was not selected for inclusion in the corresponding model. The predictor functions that were not selected in any final
model are omitted from this table. Summary predictor effects were estimated by the Dersimonian and Laird method, as REML did
not converge for the estimation of some models. Although REML has better theoretical properties for the heterogeneity estimate, the
difference for the summary effects (presented here) is limited.
Abbreviations: AGini, Gini’s mean difference of MSE; AM, average of MSE; ARE1 , random effects meta-analytic estimate of mean of
MSE; ARE0 , random effects meta-analytic estimate of heterogeneity of distribution of MSE; ARE1∕2 , sum of random effects
meta-analytic estimates of mean and heterogeneity of distribution of MSE; ASD, standard deviation of MSE; DVT, deep vein
thrombosis; MSE, mean square error; (S)IECV, (stepwise) internal-external cross-validation.
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Measure Strategy ARE1 95% CI 95% PI
Calibration slope None 1.00 0.83:1.16 0.53:1.46
AM 0.92 0.80:1.04 0.59:1.26
ARE1 0.92 0.80:1.04 0.59:1.26
ARE1∕2 0.85 0.73:0.97 0.48:1.22
ARE0 0.87 0.73:1.00 0.46:1.27
ASD 0.85 0.73:0.97 0.48;1.22
AGini 0.94 0.82:1.07 0.57:1.32
Calibration-in-the-large None 0.03 −0.33:0.39 −1.22:1.27
AM −0.06 −0.46:0.35 −1.47:1.35
ARE1 −0.06 −0.46:0.35 −1.47:1.35
ARE1∕2 0.16 −0.25:0.58 −1.27:1.60
ARE0 −0.04 −0.47:0.39 −1.51:1.43
ASD 0.16 −0.25:0.58 −1.27:1.60
AGini −0.20 −0.61:0.21 −1.63:1.23
c-Statistic None 0.68 0.65:0.71 0.60:0.75
AM 0.81 0.78:0.84 0.70:0.89
ARE1 0.81 0.78:0.84 0.70:0.89
ARE1∕2 0.81 0.79:0.84 0.73:0.88
ARE0 0.81 0.79:0.84 0.71:0.89
ASD 0.81 0.79:0.84 0.73:0.88
AGini 0.81 0.77:0.84 0.68:0.90
Note: None: model with no predictor selection.
Abbreviations: 95% CI, 95% confidence interval; 95% PI, the random effects meta-analysis approximate
95% prediction intervals lower and upper bound; AGini, Gini’s mean difference of MSE; AM, average of
MSE; ARE1 , random effects meta-analytic estimate of mean of MSE; ARE0 , random effects meta-analytic
estimate of heterogeneity of distribution of MSE; ARE1∕2 , sum of random effects meta-analytic estimates
of mean and heterogeneity of distribution of MSE; ASD, standard deviation of MSE; DVT, deep vein
thrombosis; MSE, mean square error; SIECV, stepwise internal-external cross-validation.
T A B L E 7 Meta-analysis summary
estimates of SIECV performance of six
strategies for predicting DVT
model specification as the ASD strategy. As the SIECV allows for the estimation of any performance statistic, we assessed
discriminatory performance with the c-statistic, and calibration with the calibration slope and calibration-in-the-large,
for the final model for each aggregated loss function. Subsequently, we summarized the performance and heterogeneity
thereof with univariate random effects meta-analyses.
In terms of calibration slopes (also estimated with Firth’s correction), all strategies showed some overfit (summary
calibration slope < 1), though to varying degrees (Table 7, Figure 1). Slopes <1 imply that the estimated slopes were
too large (the log odds ratios deviated too far from 0), which yielded predictions for individuals that were too extreme.
The linear predictors in the ASD strategy and the meta-analytic strategy that combined heterogeneity of performance and
average performance (ARE1∕2 ) were the worst calibrated (calibration slope of 0.85), and the AGini strategy the best (0.94).
There was substantial heterogeneity in the estimated calibration slopes, especially for the predefined model with no
predictor selection. For all strategies, the prediction interval for the calibration slope also included values >1, which
implies that for some (future) clusters the log odds ratios will probably not deviate from 0 enough and that predictions for
individuals will probably be not extreme enough. The heterogeneity of the calibration slope decreased for all strategies,
as compared to the predefined model with no added predictors. This means that for the resulting models there was a
decreased need for extensive local updating.
In terms of average calibration-in-the-large, all strategies achieved a reasonable calibration-in-the-large, that is close
to zero (Table 7, Figure 2). This means that on average the incidence was predicted accurately. On the other hand, the






























































































-1 0 1 2
Calibration Slope
(F)
F I G U R E 1 Forest plots of SIECV estimates of calibration slopes of six strategies for predicting DVT
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F I G U R E 2 Forest plots of SIECV estimates of calibration-in-the-large of six strategies for predicting DVT
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F I G U R E 3 Forest plots of SIECV estimates of c-statistics of six strategies for predicting DVT
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meta-analysis of the calibration-in-the-large showed that the heterogeneity of calibration-in-the-large had increased for
all modeling strategies, as compared to the predefined model with no added predictors. Hence, a trade-off occurred
between (heterogeneity of) calibration slopes and calibration-in-the-large, and local updating of the intercept will remain
necessary.
All strategies that applied SIECV achieved an internally-externally validated c-statistic value of 0.81 (Table 7, Figure 3).
There were small differences in heterogeneity of discrimination performance. The ASD strategy and the strategies that
included the meta-analytic estimate of heterogeneity had smaller values for the heterogeneity of the internally-externally
validated c-statistic, than the strategies that focused on the mean performance alone (AM and ARE1 ). Further, the AGini
strategy, a non-meta-analytic strategy that focuses on heterogeneity of performance, yielded larger heterogeneity of
discrimination performance.
As a final step, one must choose which modeling strategy is most likely to yield adequate performance when applied
to individuals in a new cluster, if any. Although heterogeneity in the slopes had decreased substantially for all strategies,
the prediction intervals still indicated that updating may be necessary. Further, the models resulting from all strategies
are likely to need an intercept update. In terms of calibration, it may therefore not be advisable to develop a global model,
that is a model developed on all available clusters (without leaving any out). Finally, although the discrimination for all
models improved substantially, the diagnostic utility would have to be put into a clinical perspective.
5 MOTIVATING EXAMPLE 3: PREDICTING ATRIAL FIBRILLATION
Patients with atrial fibrillation (AF) are at an increased risk for stroke.73 Although stroke is usually not fatal, it often
results in neurological deficiencies.74 In patients with AF the incidence of stroke as well as the incidence of death from
stroke can be greatly reduced by oral anticoagulation.75
For illustrative purposes, we here consider the development and validation of a binary logistic prediction model to
estimate the probability that atrial fibrillation is present in an individual patient. Previously, Audigier et al prepared a
simulated data set to mimic the patients from 28 cohorts (clusters, from hereon) of the GREAT consortium.76,77 This data
set comprises a total of 11 685 patients of which 3335 have AF.
Because some of the clusters are very small and may thereby cause estimation issues during model development
or validation, we removed a total of eight clusters in which fewer than 50 patients had the outcome or did not have
the outcome. Missing values were imputed using a joint model with random effects.30,78 As we apply the methodol-
ogy for illustrative purposes only, we have used only the first imputed data set for analyses. We subsequently modeled
the probability of the presence of atrial fibrillation in 10 873 patients from the remaining 20 clusters (Table 8). To fur-
ther prevent overfitting, we applied Firth’s correction,60 and re-estimated the intercepts with unpenalized maximum
likelihood.62
We considered seven candidate predictors, consisting of gender (binary) and six continuous predictors: body mass
index (BMI), age, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and brain natriuretic
Outcome: AF No Yes Total
Gender 0 4583 (71.3) 1844 (28.7) 6427
1 3059 (68.8) 1387 (31.2) 4446
BMI Mean (SD) 27.3 (5.7) 27.4 (5.8) 27.4 (5.7)
Age Mean (SD) 67.7 (14.1) 73.1 (13.1) 69.3 (14.0)
SBP Mean (SD) 135.6 (32.2) 135.3 (32.1) 135.5 (32.2)
DBP Mean (SD) 78.6 (18.3) 79.1 (18.4) 78.7 (18.3)
HR Mean (SD) 88.0 (25.0) 96.4 (29.0) 90.5 (26.5)
BNP Mean (SD) 3.0 (0.9) 2.9 (1.0) 2.9 (0.9)
Abbreviations: AF, atrial fibrillation; BMI, body mass index; BNP, brain natriuretic peptide; DBP,
diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure; SIECV, stepwise internal-external
cross-validation.
T A B L E 8 Clinical characteristics of AF
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peptide (BNP). BMI, age, and HR were divided by 25, and SBP and DBP by 100 to increase the absolute values of their coef-
ficients. For each of the continuous predictors, we considered linear and quadratic terms and applied centering (within
clusters) before application of the quadratic function. This was necessary to ensure that the coefficients are stabilized
and positive coefficients for quadratic terms represent an increased probability of presence of AF for values that deviate
from the mean value. Again, we stress that in practice the in- or exclusion of predictor functions should not be based on
a statistical criterion alone, but should be carefully considered as discussed in Sections 4 and 6.1.
Here, we implement the proposed predictor selection procedures to illustrate their impact on average performance as
well as on generalizability across the different clusters. We follow the SIECV strategy for model development as described
in Section 3, apply the MSE to the predicted probabilities in the hold-out clusters and apply the aggregated loss functions
on the MSE estimates and SEs thereof, to select predictors functions as we outlined in Section 3.2.
The six applied aggregated loss functions lead to four different model specifications (Table 9), as the strategy that
ignores clustering when quantifying generalizability (AM) and the strategy that optimized the meta-analytic mean of
performance (ARE1 ) lead to the same model specification. Further, both meta-analytic strategies that directly quantified
heterogeneity of performance (ASD and AGini) lead to the same model. Again, we assessed performance with the calibra-
tion slope, calibration-in-the-large, and c-statistic, and summarized these and the heterogeneity thereof with univariate
random effects meta-analyses.
In terms of summary calibration slopes (estimated with Firth’s correction and then pooled in a meta-analysis), all
strategies were rather well calibrated, showing only minor overfit (Table 10, Figure 4). However, there was substantial
heterogeneity of the calibration slopes. The approximate 95% prediction interval of the calibration slopes of the models
for the AM and ARE1 were the widest, as the upper bound reached 2.20 and the lower bound was estimated at a −0.24, as
well as the slopes for ARE1∕2 which were −0.26 to 2.18. These negative values for the lower bound imply that the predictive
effect for the models might be reversed in some clusters: individuals with AF received lower probabilities of AF than
individuals without AF in these clusters. This means that for each of these models, there was still a need for extensive
updating or model redevelopment.
Calibration-in-the-large was (near) perfect (Table 10, Figure 5). The ARE0 , ASD, and AGini strategies all achieved
a calibration-in-the-large of 0.00 (95% CI: −0.28 to 0.29), whereas those of AM and ARE1 were hardly different with
0.04 (95% CI: −0.24 to 0.33), and neither was the interval for ARE1∕2 with 0.04 (95% CI: −0.25 to 0.32). Again, there
T A B L E 9 Estimated regression
coefficients of seven models for predicting
AF estimated with SIECV
Predictor AM ARE1 ARE1∕2 ARE0 ASD AGini
Intercept −0.87 −0.87 −0.85 −0.84 −0.81 −0.81
Gender −0.08 −0.08
Age/25 0.75 0.75 0.74 0.59 0.62 0.62
HR/25 0.29 0.29 0.32
SBP/100 −0.59 −0.59
DBP/100 −0.59
(Age/25)2 −0.17 −0.17 −0.14
(BMI/25)2 0.37 0.37 0.40 0.32 0.32 0.32
(SBP/100)2 0.28 0.28
(BNP)2 0.03 0.03 0.03
Note: Empty cells indicate the predictor was not selected for inclusion in the corresponding model. The
predictor functions that were not selected in any final model are omitted from this table. Summary
predictor effects were estimated by the Dersimonian and Laird method, as REML did not converge for
the estimation of some models. Although REML has better theoretical properties for the heterogeneity
estimate, the difference for the summary effects (presented here) is limited.
Abbreviations: AGini, Gini’s mean difference of MSE; AM, average of MSE; ARE1 , random effects
meta-analytic estimate of mean of MSE; ARE0 , random effects meta-analytic estimate of heterogeneity
of distribution of MSE; ARE1∕2 , sum of random effects meta-analytic estimates of mean and
heterogeneity of distribution of MSE; ASD, standard deviation of MSE; AF, atrial fibrillation; BMI, body
mass index; BNP, brain natriuretic peptide; DBP, diastolic blood pressure; HR, heart rate; MSE, mean
square error; SBP, systolic blood pressure; SIECV, stepwise internal-external cross-validation.
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Measure Strategy ARE1 95% CI 95% PI
Calibration slope AM 0.98 0.70:1.27 −0.24:2.20
ARE1 0.98 0.70:1.27 −0.24:2.20
ARE1∕2 0.96 0.68:1.24 −0.26:2.18
ARE0 0.98 0.74:1.23 0.03:1.94
ASD 0.95 0.70:1.20 −0.02:1.91
AGini 0.95 0.70:1.20 −0.02:1.91
Calibration intercept AM 0.04 −0.24:0.33 −1.25:1.34
ARE1 0.04 −0.24:0.33 −1.25:1.34
ARE1∕2 0.04 −0.25:0.32 −1.25:1.33
ARE0 0.00 −0.28:0.29 −1.28:1.28
ASD 0.00 −0.28:0.29 −1.28:1.28
AGini 0.00 −0.28:0.29 −1.28:1.28
c-Statistic AM 0.62 0.58:0.65 0.46:0.75
ARE1 0.62 0.58:0.65 0.46:0.75
ARE1∕2 0.62 0.58:0.65 0.46:0.75
ARE0 0.58 0.56:0.60 0.51:0.65
ASD 0.58 0.56:0.60 0.49:0.66
AGini 0.58 0.56:0.60 0.49:0.66
Abbreviations: 95% CI, 95% confidence interval; 95% PI, the random effects meta-analysis
approximate 95% prediction intervals lower and upper bound; AGini, Gini’s mean difference of
MSE; AM, average of MSE; ARE1 , random effects meta-analytic estimate of mean of MSE; ARE0 ,
random effects meta-analytic estimate of heterogeneity of distribution of MSE; ARE1∕2 , sum of
random effects meta-analytic estimates of mean and heterogeneity of distribution of MSE; ASD,
standard deviation of MSE; AF, atrial fibrillation; MSE, mean square error; SIECV, stepwise
internal-external cross-validation.
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estimates of SIECV performance of six strategies
for predicting AF
was large heterogeneity in calibration-in-the-large, as shown by the approximate 95% prediction intervals of the
calibration-in-the-large. This means that for each of these models there was still a need for intercept updating they may
be used.
The AM, ARE1 , and ARE1∕2 strategies attained a somewhat better discrimination with c-statistics of 0.62 (95% CI: 0.58 to
0.65) than the other strategies, that all attained c-statistics of 0.58 (95% CI: 0.56 to 0.60), respectively (Table 10, Figure 6).
There was considerable heterogeneity in the c-statistics for all strategies. The discrimination was worse than random
(c-statistic < 0.50) in at least one cluster for each of the strategies. Indeed, the approximate 95% prediction interval shows
it is most likely that this will occur in a new cluster for the AM and ARE1 strategies.
For all of the considered strategies the SIECV shows that although calibration was adequate on average and that overall
discrimination was modest, it is not very likely that any of the developed models will perform well at predicting AF in
new clusters without local updating. The effects of the included predictors vary substantially across clusters and hence
heterogeneity of performance could not be resolved by considering nonlinear terms. The used for these analyses can be
found on Github (https://github.com/VMTdeJong/SIECV-AF).
6 GENERAL DISCUSSION
We proposed a methodology for improving the generalizabilty of prediction models developed across different settings
and populations when individual participant data from multiple studies or electronic health records are available. Our
methodology is aimed at situations where the goal is to produce a single model that can globally be used across a wide vari-
ety of settings without having to update or recalibrate predictor effects (although it still allows intercepts to be updated).
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F I G U R E 4 Forest plots of SIECV estimates of calibration slopes of six strategies for predicting AF
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F I G U R E 5 Forest plots of SIECV estimates of calibration-in-the-large of six strategies for predicting AF
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F I G U R E 6 Forest plots of SIECV estimates of c-statistics of six strategies for predicting AF
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This methodology leverages the information from multiple clusters (eg, studies) by iteratively using all but one cluster
for model development and assessing performance in the remainder.
The overall predictive performance and its variation across clusters can then be used to quantify a model’s generaliz-
ability across clusters, and to inform the selection of predictors. As we have demonstrated in our motivating examples, the
selection of predictors based on the proposed aggregated loss functions can lead to differing model specifications. Each
model specification may perform differently in predicting the outcome for individuals in differing clusters, leading to
differing average and heterogeneity of calibration and discrimination. Trade-offs may occur between discrimination and
calibration as well as between average and heterogeneity of performance. These may be quantified in the SIECV algorithm
during model development, by which the need for extensive or local model updating may be assessed immediately. For
instance, before validation in the hold-out cluster, the intercept may be updated, which will inform the researcher on the
generalizability of performance of the model after local updates.
Although it remains unlikely that SIECV can completely resolve the need for an intercept update, it may reduce
the necessity of the local tailoring of prediction models (particularly with respect to the calibration slope), which is
highly prevalent in the implementation of today’s prediction models. In particular, we aimed to reduce the need for
re-estimation of individual predictor effects. Evidently, the potential impact of SIECV strongly depends on the availability
of patient-level covariates that may explain heterogeneity in predictive associations.
We discussed a variety of aggregated loss functions for quantifying the generalizability of a developed model. These
ranged from producing an average performance estimate to quantifying its dispersion across clusters. Our framework
also allows for assessing average and heterogeneity of performance across data sets (clusters) through meta-analysis,
and formalizes the predictor function selection by both of these simultaneously. This requires specifying the relative
importance of average performance and the heterogeneity thereof on beforehand. For the meta-analysis strategy, this
either requires the prespecification of 𝜆, or the finding of an optimal value for 𝜆 through a resampling method. When
applied in the SIECV model development process, these measures lead to different model specifications with different
average performance and heterogeneity thereof, as each places different importance thereon. Therefore, the researcher
will have to choose whether to optimize average calibration (calibration-in-the-large close to 0, slope close to 1) and
discrimination (high c-statistic, positive and/or negative predictive value for its clinical issue), or the heterogeneity of one
or both of these across clusters.
6.1 Limitations and future directions
Our main focus was on informing the selection of predictors in the analysis of multiple studies or EHR, and not on the
estimation of corresponding predictor effects. Hence, the impact of our methodology may be limited in cases where the
number of available predictors is low or when available predictors are not related to heterogeneity in predictor-outcome
associations. Though, even in cases where we have few predictors, it may still prove worthwhile to consider nonlinear
terms and interaction effects by the use of SIECV.
Improvements in one prediction model performance measure may come at the cost of those in another measure. For
instance, an improvement in calibration may result in a deterioration in discrimination. In our motivating example, the
predictor d-dimer had a large predictive effect, and substantially contributed to discrimination performance. However,
d-dimer was a dichotomized predictor and was measured using different methods across clusters.58,79 This resulted in
substantial heterogeneity in its regression coefficients and in heterogeneity of its diagnostic accuracy (see Reference 80).
Differences in predictor distributions will have an impact on the discrimination of an estimated model:31 in fact, the
c-statistic is directly related to the SD of the linear predictor.81 Differences in predictor distributions should not have
any impact on the calibration,31 as long as all predictors have been measured and included (with the right functional
form) in the prediction model, and all of the regression coefficients are correct and there is no heterogeneity in the true
regression coefficients. However, differences in distributions of unmeasured predictors will have an impact on the model’s
calibration. If these predictors are correlated with measured predictors, this will appear as miscalibration of the linear
predictor (ie, the calibration slope) and possibly the intercept. Including this predictor in the prediction model—if it
were measured—would then remove this miscalibration, thereby improving performance. If the unmeasured predictor
is not related to any included predictors, the prediction model’s miscalibration will appear solely as miscalibration of the
intercept or calibration-in-the-large. In other words, if the distribution of a predictor changes, the predicted incidence of
the outcome should change accordingly. If that predictor is not measured it will not affect the predictions, which leads to
miscalibration.
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Imprecise regression coefficients may impact each aspect of performance. If all predictors’ k coefficients are too large
for the validation sample, the calibration slope will be <1, but discrimination will be unaffected. If some are too large and
some too small, the discrimination will also be deteriorated. If the model’s intercept is incorrect, or if it cannot account
for differences in predictor effects, the calibration-in-the-large will be affected, but not the discrimination.
To gain an understanding of the possible values for performance the prediction model may have in a new sample,
the use of benchmark values has been proposed.31,82 Most importantly, the case-mix corrected c-statistic disentangles the
effects of case-mix and incorrect coefficients between clusters. It assumes the predictor coefficients are valid and adjusts
for the case-mix of the validation sample.31 An alternative approach is to quantify the relatedness of the different clusters
using a membership model.14
In this article, we have focused on improving the generalizability of a model’s predictive performance through the
addition or removal of predictors or functions of predictors. However, this may lead to instability in the estimation process
and overfitting of the predictor coefficients if not enough data are available or the outcome is too rare. We stress that the
proposed methodology is only likely to lead to stable estimates for the predictor effects when large data sets are available.
A future step may be to incorporate heterogeneity of performance into the estimation process. For instance, in penalized
maximum likelihood estimation a penalty for heterogeneity of predictor coefficients or predictive performance across
clusters could be applied. Such a penalty could readily produce more generalizable models, without the need for a stepwise
selection process.
We have not performed a simulation study to compare the aggregated loss functions. Such an endeavor might not be
fruitful, as it should be obvious that each of these measures for predictor selection would lead to different estimates of
both average and heterogeneity of performance, that is, there is no gold standard. As each of the aggregated loss functions
serve a different goal, it is unclear what the evaluation criteria in such a simulation study would be. Nevertheless, it may
still be helpful to assess under what circumstances certain generalizability measures may be preferred.
Whereas methodology has been developed on dealing with missing data in model validation in general (eg, see Ref-
erence 83), more guidance is needed for application to SIECV. In general, the use of multilevel imputation methods have
been recommended in IPD-MA and in the analysis of other types of clustered data.76,84-86 These methods can account for
variables that are sporadically missing within one or more clusters, but also impute variables that are not measured in
certain clusters.85 The adoption of multilevel imputation methods therefore seems paramount when adopting SIECV in
data sets with missing values. Further, in multiple imputation it is imperative that the imputation model includes the all
of the variables used in the analysis model, including the outcome, as well as any other predictive variables.87 For this
reason, we recommend to include all candidate predictors of SIECV in the imputation model, and to allow for random
effects for all of these. Recently, several authors evaluated approaches for implementing multiple imputation in an inter-
nal validation procedure. Notably, Schomaker and Heumann showed that the bootstrap and multiple imputation can be
applied in sequence to obtain valid SEs, and give recommendations on its implementation.88 Further, Wahl et al. recom-
mend that the multiple imputation procedure is performed within the development and validation sets separately, for
each split in a k-fold cross-validation,89 which could readily be extended to IECV. Extension to SIECV, however, would
require either an appropriate synthesis of performance estimates across imputed data sets within studies before calcula-
tion of the aggregate loss function and predictor selection, or an appropriate synthesis of selected predictors in different
imputed data sets. For the latter, a voting strategy may be applied.90,91 When data are missing sporadically and a two-stage
meta-analysis approach is taken, the imputation procedure might be performed within clusters before applying SIECV.
A formal comparison of these strategies is still needed.
7 CONCLUSION
The IECV methodology for model validation can inform the researcher on the need for updating a prediction model
to adapt it to particular populations and settings, when IPD from multiple clusters or studies are available. Our SIECV
methodology extends this framework to quantify and reduce the impact of any heterogeneity on prediction model perfor-
mance. This can inform the researcher and may reduce the need for tailoring the prediction model to specific populations
and settings.
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